Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment

Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment

Submitted by admin on November 18, 2024 - 6:30pm
Source: 
Clinical Trials Arena
News Tags: 
Alnylam Pharmaceuticals
nucresiran
RNAi
clinical trials
Headline: 
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
snippet: 

Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference (RNAi) therapeutic for transthyretin (ATTR) amyloidosis treatment.

Do Not Allow Advertisers to Use My Personal information